1. Home
  2. BANL vs INAB Comparison

BANL vs INAB Comparison

Compare BANL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

HOLD

Current Price

$0.67

Market Cap

17.2M

Sector

Energy

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.46

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANL
INAB
Founded
2015
2016
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
14.2M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
BANL
INAB
Price
$0.67
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
434.5K
73.8K
Earning Date
12-03-2025
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.12
52 Week High
$1.16
$4.20

Technical Indicators

Market Signals
Indicator
BANL
INAB
Relative Strength Index (RSI) 48.12 39.62
Support Level $0.63 $1.17
Resistance Level $0.77 $2.59
Average True Range (ATR) 0.09 0.17
MACD -0.01 -0.03
Stochastic Oscillator 22.17 8.57

Price Performance

Historical Comparison
BANL
INAB

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: